Association between the characteristics of metabolic syndrome and Alzheimer's disease

Metabolic Brain Disease

Volumn 28, Issue 4, 2013, Pages 597-604

  Yang, Hui Ting ^a   Sheen, Yi Jing ^b   Kao, Chuen Der ^b   Chang, Chin An ^c   Hu, Ya Chun ^a   Lin, Jiann Liang ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG HOSPITAL   (Taiwan)

^c CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

Alzheimer's disease (AD); Amyloid beta 42 (A 42); Amyloid precursor protein (APP); Metabolic syndrome

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; INSULIN; INSULIN RECEPTOR; MALONALDEHYDE; STREPTOZOCIN; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN TISSUE; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; LIPID DIET; LIPID LIVER LEVEL; LIVER; MALE; METABOLIC SYNDROME X; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RECEPTOR DOWN REGULATION; STREPTOZOCIN DIABETES;

ANIMALIA; RATTUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD GLUCOSE; BRAIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOWN-REGULATION; INSULIN; LIVER; MALE; METABOLIC SYNDROME X; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, INSULIN;

EID: 84887233266     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9406-2     Document Type: Article

References (32)

1. Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G (2012) Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 15:217-221
2. Arab L, Sadeghi R, Walker DG, Lue LF, Sabbagh MN (2011) Consequences of aberrant insulin regulation in the brain: can treating diabetes be effective for Alzheimer's disease. Curr Neuropharmacol 9:693-705
3. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M (2004) Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63:828-831
4. Bazan NG, Colangelo V, Lukiw WJ (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69:197-210
5. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24:114-127
6. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162:313-319
7. Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci Biobehav Rev 35:1397-1409
8. d'Abramo C, Ricciarelli R, Pronzato MA, Davies P (2006) Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. J Neurochem 98:1068-1077
9. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10:89-109
10. de la Torre JC (1994) Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Biobehav Rev 18:397-401
11. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100:4162-4167
12. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60:958-964
13. Goyal BR, Parmar K, Goyal RK, Mehta AA (2011) Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacol Rep 63:956-966
14. Iverson SJ, Lang SL, Cooper MH (2001) Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 36:1283-1287
15. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P (2008) Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7:812-826
16. Kroner Z (2009) The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 14:373-379
17. Lee YH, Martin JM, Maple RL, Tharp WG, Pratley RE (2009) Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology 90:383-390
18. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9:13-33
19. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65:776-785
20. Lu J, Wu DM, Zheng ZH, Zheng YL, Hu B, Zhang ZF (2011) Troxerutin protects against high cholesterol-induced cognitive deficits in mice. Brain 134:783-797
21. Mihara M, Uchiyama M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271-278
22. Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z (2010) High normal fasting blood glucose is associated with dementia in Chinese elderly. Alzheimers Dement 6:440-447
23. Park SA (2011) A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 7:10-18
24. Raffai RL, Weisgraber KH (2003) Cholesterol: from heart attacks to Alzheimer's disease. J Lipid Res 44:1423-1430
25. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alperovitch A, Barberger-Gateau P (2009) Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32:169-174
26. Sankar P, Subhashree S, Sudharani S (2012) Effect of Trigonella foenum-graecum seed powder on the antioxidant levels of high fat diet and low dose streptozotocin induced type II diabetic rats. Eur Rev Med Pharmacol Sci 16(Suppl 3):10-17
27. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS (2011) Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 89:808-814
28. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72:850-855
29. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5:655-660
30. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67:843-847
31. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL (2010) Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 55:931-940
32. Zhang M, Lv XY, Li J, Xu ZG, Chen L (2008) The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008:704045